Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL712577 | 0.82 | EPHX1 (0.30) | EPHX1 | |
| SCHEMBL712104 | 0.82 | — | — | |
| SCHEMBL13358783 | 0.78 | — | — | |
| SCHEMBL4499014 | 0.77 | EPHX1 (0.42) | EPHX1 | |
| SCHEMBL21582231 | 0.77 | EPHX1 (0.42) | EPHX1 | |
| SCHEMBL714714 | 0.74 | — | — | |
| SCHEMBL714070 | 0.72 | — | — | |
| SCHEMBL13358781 | 0.71 | KCNA4 (0.36) | — | |
| SCHEMBL10207850 | 0.70 | MGAM (0.34) | — | |
| SCHEMBL3250389 | 0.67 | MAPK1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124780-B2 | Benzimidazole compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-02-28 | — | — | US | disclosed |
| US-8124780-B2 | Benzimidazole compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-02-28 | — | — | US | disclosed |
| US-8124780-B2 | Benzimidazole compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-02-28 | — | — | US | disclosed |
| US-20110009624-A9 | BENZIMIDAZOLE COMPOUNDS HAVING GASTRIC ACID SECRETION INHIBITORY ACTION | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20110009624-A9 | BENZIMIDAZOLE COMPOUNDS HAVING GASTRIC ACID SECRETION INHIBITORY ACTION | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-01-13 | — | — | US | disclosed |
| EP-1870409-B1 | BENZIMIDAZOLE COMPOUNDS | EISAI R&D MAN CO LTD (JP) | 2010-05-12 | — | — | EP | disclosed |
| EP-1870409-B1 | BENZIMIDAZOLE COMPOUNDS | EISAI R&D MAN CO LTD (JP) | 2010-05-12 | — | — | EP | disclosed |
| US-20090292120-A1 | BENZIMIDAZOLE COMPOUNDS HAVING GASTRIC ACID SECRETION INHIBITORY ACTION | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-26 | — | — | US | disclosed |
| US-20090292120-A1 | BENZIMIDAZOLE COMPOUNDS HAVING GASTRIC ACID SECRETION INHIBITORY ACTION | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-26 | — | — | US | disclosed |
| US-20090203911-A1 | BENZIMIDAZOLE COMPOUND | MIYAZAWA SHUHEI | 2009-08-13 | — | — | US | disclosed |
| US-7425634-B2 | Benzimidazole compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-09-16 | — | — | US | disclosed |
| US-7425634-B2 | Benzimidazole compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-09-16 | — | — | US | disclosed |
| EP-1870409-A1 | BENZIMIDAZOLE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-12-26 | — | — | EP | disclosed |
| EP-1870409-A1 | BENZIMIDAZOLE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-12-26 | — | — | EP | disclosed |
| US-20070015782-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-18 | — | — | US | disclosed |
| US-20070015782-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-18 | — | — | US | disclosed |
| US-20070015782-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-18 | — | — | US | disclosed |
| US-20070010542-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-11 | — | — | US | disclosed |
| US-20070010542-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-11 | — | — | US | disclosed |
| US-20070010542-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090292120-A1 | BENZIMIDAZOLE COMPOUNDS HAVING GASTRIC ACID SECRETION INHIBITORY ACTION | GIPR, HRH2, SI | EPHX1 1030/4885 |
| US-20110009624-A9 | BENZIMIDAZOLE COMPOUNDS HAVING GASTRIC ACID SECRETION INHIBITORY ACTION | GIPR, HRH2, SI | EPHX1 1030/4885 |
| US-20070010542-A1 | Benzimidazole compound | HRH2, GIPR, HRH4 | EPHX1 1073/4885 |
| US-20090203911-A1 | BENZIMIDAZOLE COMPOUND | HRH2, HRH4, HRH1 | EPHX1 999/4885 |
| US-20070015782-A1 | Benzimidazole compound | HRH2, GIPR, HRH4 | EPHX1 1073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.